Media & Press
New Study Shows Benefits of Caffeine For Pre-Term Babies
Phebra has welcomed the findings of a landmark new study which shows the sustained benefits of giving neonatal caffeine to pre-term babies suffering breathing difficulties.
Sodium Bicarbonate US Supply Agreement
Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.
Phebra Welcomes PBS Listing for Leukaemia Treatment
Phebra has welcomed the listing on the Australian PBS of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).
Clinical Trial for Jellyfish Sting Antidote
Phebra is supporting a new clinical trial to test the efficacy of Magnesium Sulphate as an antidote for Irukandji Syndrome (IS), the acute pain caused by certain jellyfish stings.
Manufacturing and Product Supply Underway at New Phebra Plant
Phebra’s manufacturing and product supply from its new sterile manufacturing plant is underway.
Australian Distribution of Syntometrine
Phebra announces an agreement with Alliance Pharma to supply Syntometrine to the Australian market.
Phebra’s New Energy Efficiency Program
Phebra is ‘going green’ and implementing an energy efficiency program at the new manufacturing plant.
New Phebra Plant receives TGA manufacturing licence
Phebra welcomes the granting of its licence from the TGA for its new sterile manufacturing plant
Industry and Innovation Minister Greg Combet Opens New Phebra Pharmaceutical Plant
Federal Minister for Industry and Innovation, Greg Combet, officially opened and inspected Phebra’s new sterile manufacturing plant.
Phebra commences validation manufacturing at new plant
The first stage of validation manufacturing at Phebra’s new plant begins